Decoy Therapeutics Inc.: 10-Q/A filed 2020-05-15
What Decoy Therapeutics Inc. reported in its quarterly report amendment filed 2020-05-15 (fiscal Q1 2020): 27 published measures, 58 facts as tagged in accession 0001615219-20-000061.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2020-05-15
- Fiscal period
- fiscal Q1 2020
- Accession
- 0001615219-20-000061 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 20,065,374 | USD | |
| At 2019-12-31 | 13,894,398 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 2,062,761 | USD | |
| At 2019-12-31 | 3,313,544 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 18,002,613 | USD | |
| At 2019-12-31 | 10,580,854 | USD | |
| At 2019-03-31 | 1,730,282 | USD | |
| At 2018-12-31 | -1,271,114 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 9,646,940 | USD | |
| At 2019-12-31 | 3,738,900 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -2,083,816 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,522,076 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -3,708,034 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,868,713 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 1,132,830 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 655,635 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 9,616,074 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 1,508,179 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | -14,160,516 | USD | |
| At 2019-12-31 | -12,076,700 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 21,889 | USD | |
| At 2019-12-31 | 25,016 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 38,409 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 35,407 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -2,369,558 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,532,784 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 10,884,429 | USD | |
| At 2019-12-31 | 4,694,799 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 979,823 | USD | |
| At 2019-12-31 | 1,790,966 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 8,865,909 | USD | |
| At 2019-12-31 | 8,865,909 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 3,502,388 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 2,188,419 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 1,643,371 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 699,929 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 13,645,677 | shares | |
| At 2019-12-31 | 4,511,174 | shares |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 9,646,940 | USD | |
| At 2019-12-31 | 3,738,900 | USD | |
| At 2019-03-31 | 5,771,247 | USD | |
| At 2018-12-31 | 6,131,781 | USD |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 32,161,718 | USD | |
| At 2019-12-31 | 22,657,103 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 293,147 | USD | |
| At 2019-12-31 | 308,674 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 646,360 | USD | |
| At 2019-12-31 | 955,899 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-03-31 | 0 | USD | |
| At 2019-12-31 | 541,701 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 1,859,017 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 1,488,490 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 4,233 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 114,707 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 3,061 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 0 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | -911,301 | USD | 91 |
| 2019-01-01 to 2019-03-31 | 589,700 | USD | 90 |
Inspect the source
- Entity
- Decoy Therapeutics Inc. / CIK 0001615219
- Captured
- 2026-09-21T17:20:32.388Z
- SEC response SHA-256
3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))